ZA200603420B - Osmotically driven active agent delivery device providing an ascending release profile - Google Patents

Osmotically driven active agent delivery device providing an ascending release profile Download PDF

Info

Publication number: ZA200603420B
Authority: ZA; South Africa
Prior art keywords: osmotic pump; osmotic; rate; permeability; rate controlling
Prior art date: 2003-09-30

Application number

ZA200603420A

Other languages

English (en)

Inventor

Chen Guohua

Lautenbach Scott

Rupal A Ayer

Original Assignee

Alza Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-30

Filing date

2006-04-28

Publication date

2007-07-25

2006-04-28 Application filed by Alza Corp filed Critical Alza Corp

2007-07-25 Publication of ZA200603420B publication Critical patent/ZA200603420B/en

Links

239000013543 active substance Substances 0.000 title claims description 90
230000001174 ascending effect Effects 0.000 title claims description 35
230000003204 osmotic effect Effects 0.000 claims description 333
239000000463 material Substances 0.000 claims description 225
239000012528 membrane Substances 0.000 claims description 156
230000035699 permeability Effects 0.000 claims description 130
239000000203 mixture Substances 0.000 claims description 117
230000002708 enhancing effect Effects 0.000 claims description 72
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
238000009472 formulation Methods 0.000 claims description 36
230000001965 increasing effect Effects 0.000 claims description 35
239000012530 fluid Substances 0.000 claims description 34
229920002678 cellulose Polymers 0.000 claims description 21
239000001913 cellulose Substances 0.000 claims description 18
229920000642 polymer Polymers 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 16
238000000034 method Methods 0.000 claims description 14
239000002357 osmotic agent Substances 0.000 claims description 13
239000011148 porous material Substances 0.000 claims description 12
239000011159 matrix material Substances 0.000 claims description 11
230000015556 catabolic process Effects 0.000 claims description 10
238000006731 degradation reaction Methods 0.000 claims description 10
229920001610 polycaprolactone Polymers 0.000 claims description 10
-1 polydioanones Polymers 0.000 claims description 10
239000000945 filler Substances 0.000 claims description 9
229920001577 copolymer Polymers 0.000 claims description 8
229920000747 poly(lactic acid) Polymers 0.000 claims description 8
239000004632 polycaprolactone Substances 0.000 claims description 8
239000002861 polymer material Substances 0.000 claims description 8
230000009969 flowable effect Effects 0.000 claims description 7
229920002635 polyurethane Polymers 0.000 claims description 7
239000004814 polyurethane Substances 0.000 claims description 7
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
229920000954 Polyglycolide Polymers 0.000 claims description 5
229920001971 elastomer Polymers 0.000 claims description 5
230000007062 hydrolysis Effects 0.000 claims description 5
238000006460 hydrolysis reaction Methods 0.000 claims description 5
235000002639 sodium chloride Nutrition 0.000 claims description 5
239000002195 soluble material Substances 0.000 claims description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
238000004090 dissolution Methods 0.000 claims description 4
239000000806 elastomer Substances 0.000 claims description 4
150000004676 glycans Chemical class 0.000 claims description 4
238000000465 moulding Methods 0.000 claims description 4
229920000728 polyester Polymers 0.000 claims description 4
229920001282 polysaccharide Polymers 0.000 claims description 4
239000005017 polysaccharide Substances 0.000 claims description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
239000002202 Polyethylene glycol Substances 0.000 claims description 3
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
239000004202 carbamide Substances 0.000 claims description 3
229920003086 cellulose ether Polymers 0.000 claims description 3
230000006835 compression Effects 0.000 claims description 3
230000003628 erosive effect Effects 0.000 claims description 3
238000011049 filling Methods 0.000 claims description 3
230000004907 flux Effects 0.000 claims description 3
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
229960000367 inositol Drugs 0.000 claims description 3
INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 claims description 3
229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
235000011147 magnesium chloride Nutrition 0.000 claims description 3
229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
235000019341 magnesium sulphate Nutrition 0.000 claims description 3
229960001855 mannitol Drugs 0.000 claims description 3
150000002772 monosaccharides Chemical class 0.000 claims description 3
229920001542 oligosaccharide Polymers 0.000 claims description 3
150000002482 oligosaccharides Chemical class 0.000 claims description 3
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 3
239000004417 polycarbonate Substances 0.000 claims description 3
229920000515 polycarbonate Polymers 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
235000011009 potassium phosphates Nutrition 0.000 claims description 3
239000012254 powdered material Substances 0.000 claims description 3
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
239000001488 sodium phosphate Substances 0.000 claims description 3
229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
235000011152 sodium sulphate Nutrition 0.000 claims description 3
239000000600 sorbitol Substances 0.000 claims description 3
235000002906 tartaric acid Nutrition 0.000 claims description 3
239000011975 tartaric acid Substances 0.000 claims description 3
OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 claims description 3
RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 claims description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 2
229920002732 Polyanhydride Polymers 0.000 claims description 2
229920001710 Polyorthoester Polymers 0.000 claims description 2
238000007906 compression Methods 0.000 claims description 2
230000008878 coupling Effects 0.000 claims description 2
238000010168 coupling process Methods 0.000 claims description 2
238000005859 coupling reaction Methods 0.000 claims description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 2
239000002745 poly(ortho ester) Substances 0.000 claims description 2
229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
239000004633 polyglycolic acid Substances 0.000 claims description 2
229920001855 polyketal Polymers 0.000 claims description 2
239000004626 polylactic acid Substances 0.000 claims description 2
229920006324 polyoxymethylene Polymers 0.000 claims description 2
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
239000011780 sodium chloride Substances 0.000 claims description 2
238000004891 communication Methods 0.000 claims 2
230000001276 controlling effect Effects 0.000 description 86
150000001875 compounds Chemical class 0.000 description 37
230000006870 function Effects 0.000 description 25
239000007788 liquid Substances 0.000 description 21
239000013583 drug formulation Substances 0.000 description 12
239000000499 gel Substances 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 10
238000002513 implantation Methods 0.000 description 10
238000013461 design Methods 0.000 description 9
239000003814 drug Substances 0.000 description 9
230000009286 beneficial effect Effects 0.000 description 8
229940079593 drug Drugs 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 6
238000013459 approach Methods 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
239000007943 implant Substances 0.000 description 5
238000001802 infusion Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229920006217 cellulose acetate butyrate Polymers 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
230000007613 environmental effect Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
239000012466 permeate Substances 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
238000005266 casting Methods 0.000 description 3
229920002301 cellulose acetate Polymers 0.000 description 3
230000001934 delay Effects 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
150000002739 metals Chemical class 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000007787 solid Substances 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
229910000640 Fe alloy Inorganic materials 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
229920002614 Polyether block amide Polymers 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 2
229910045601 alloy Inorganic materials 0.000 description 2
239000000956 alloy Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000000470 constituent Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000004715 ethylene vinyl alcohol Substances 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
230000035558 fertility Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 2
238000001746 injection moulding Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
229960004400 levonorgestrel Drugs 0.000 description 2
239000007769 metal material Substances 0.000 description 2
229940053934 norethindrone Drugs 0.000 description 2
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000008188 pellet Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229920013730 reactive polymer Polymers 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920008347 Cellulose acetate propionate Polymers 0.000 description 1
229920001747 Cellulose diacetate Polymers 0.000 description 1
DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
229920002284 Cellulose triacetate Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004642 Polyimide Substances 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
229920002396 Polyurea Polymers 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003139 biocide Substances 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
229920006218 cellulose propionate Polymers 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000000788 chromium alloy Substances 0.000 description 1
238000000748 compression moulding Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000007799 cork Substances 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000005553 drilling Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229940015043 glyoxal Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
229920000578 graft copolymer Polymers 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 description 1
239000011799 hole material Substances 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000000711 locust bean gum Substances 0.000 description 1
235000010420 locust bean gum Nutrition 0.000 description 1
238000003754 machining Methods 0.000 description 1
238000007726 management method Methods 0.000 description 1
229910001092 metal group alloy Inorganic materials 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000002892 organic cations Chemical class 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001084 poly(chloroprene) Polymers 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920001721 polyimide Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000005060 rubber Substances 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
238000007789 sealing Methods 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
239000002002 slurry Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
229920003048 styrene butadiene rubber Polymers 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229910052715 tantalum Inorganic materials 0.000 description 1
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229920001169 thermoplastic Polymers 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M2005/14513—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons with secondary fluid driving or regulating the infusion

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)

ZA200603420A 2003-09-30 2006-04-28 Osmotically driven active agent delivery device providing an ascending release profile ZA200603420B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US50792003P	2003-09-30	2003-09-30

Publications (1)

Publication Number	Publication Date
ZA200603420B true ZA200603420B (en)	2007-07-25

Family

ID=34421688

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200603420A ZA200603420B (en)	2003-09-30	2006-04-28	Osmotically driven active agent delivery device providing an ascending release profile

Country Status (12)

Country	Link
US (1)	US7241457B2 (zh)
EP (1)	EP1682099A2 (zh)
JP (1)	JP2007507513A (zh)
KR (1)	KR20060097008A (zh)
CN (1)	CN1859900A (zh)
AU (1)	AU2004277980A1 (zh)
BR (1)	BRPI0414941A (zh)
CA (1)	CA2538043A1 (zh)
IL (1)	IL174294A0 (zh)
MX (1)	MXPA06002967A (zh)
WO (1)	WO2005032524A2 (zh)
ZA (1)	ZA200603420B (zh)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7919109B2 (en)	1999-02-08	2011-04-05	Intarcia Therapeutics, Inc.	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en)	1999-02-08	2007-08-21	Alza Corporation	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
US7731947B2 (en) *	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
US8075872B2 (en)	2003-08-06	2011-12-13	Gruenenthal Gmbh	Abuse-proofed dosage form
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20050266087A1 (en) *	2004-05-25	2005-12-01	Gunjan Junnarkar	Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
US20060020253A1 (en) *	2004-07-26	2006-01-26	Prescott Anthony D	Implantable device having reservoir with controlled release of medication and method of manufacturing the same
US8052996B2 (en)	2005-02-03	2011-11-08	Intarcia Therapeutics, Inc.	Two-piece, internal-channel osmotic delivery system flow modulator
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7959938B2 (en)	2005-03-15	2011-06-14	Intarcia Therapeutics, Inc.	Polyoxaester suspending vehicles for use with implantable delivery systems
ES2400091T3 (es)	2005-08-11	2013-04-05	Massachusetts Institute Of Technology	Dispositivo de suministro de fármacos intravesical y método
EP1818664B1 (de)	2006-02-13	2013-05-01	F.Hoffmann-La Roche Ag	Vorrichtung zur Erkennung einer Druckänderung im Flüssigkeitspfad einer Mikrodosiervorrichtung
PT2359808E (pt)	2006-08-09	2013-08-28	Intarcia Therapeutics Inc	Sistemas de entrega osmótica e montagens de pistão
US8641660B2 (en)	2006-10-04	2014-02-04	P Tech, Llc	Methods and devices for controlling biologic microenvironments
US8617143B2 (en) *	2006-12-07	2013-12-31	The Regents Of The University Of California	Therapeutic agent delivery systems and devices
DE102007011485A1 (de)	2007-03-07	2008-09-11	Grünenthal GmbH	Darreichungsform mit erschwertem Missbrauch
US10668058B2 (en)	2007-03-30	2020-06-02	Philip Morris Products S.A.	Device and method for delivery of a medicament
PL2157967T3 (pl)	2007-04-23	2013-06-28	Intarcia Therapeutics Inc	Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
JP5774853B2 (ja)	2008-01-25	2015-09-09	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	医薬投薬形
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
EP2273983B1 (en)	2008-05-09	2016-07-20	Grünenthal GmbH	Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2010019507A2 (en) *	2008-08-09	2010-02-18	Massachusetts Institute Of Technology	Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
NZ592113A (en) *	2008-10-15	2012-04-27	Intarcia Therapeutics Inc	Highly concentrated drug particles, formulations, suspensions and uses thereof
US20100155333A1 (en) *	2008-12-18	2010-06-24	Chevron U.S.A., Inc.	Process for dewatering an aqueous organic solution
CA2765971C (en)	2009-07-22	2017-08-22	Gruenenthal Gmbh	Hot-melt extruded controlled release dosage form
EP2997965B1 (en)	2009-07-22	2019-01-02	Grünenthal GmbH	Tamper-resistant dosage form for oxidation-sensitive opioids
HUE035862T2 (en)	2009-09-28	2018-05-28	Intarcia Therapeutics Inc	Rapid establishment and/or termination of substantial steady-state drug delivery
SG188317A1 (en)	2010-08-30	2013-04-30	Sinusys Corp	Devices for dilating a paranasal sinus opening and for treating sinusitis
AR082862A1 (es)	2010-09-02	2013-01-16	Gruenenthal Gmbh	Forma de dosificacion resistente a alteracion que comprende un polimero anionico
PE20131102A1 (es)	2010-09-02	2013-10-12	Gruenenthal Chemie	Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9351924B2 (en) *	2011-03-11	2016-05-31	Snu R&Db Foundation	Drug delivery system including laminated structure
EA201400172A1 (ru)	2011-07-29	2014-06-30	Грюненталь Гмбх	Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
AR087359A1 (es)	2011-07-29	2014-03-19	Gruenenthal Gmbh	Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
EP2819656A1 (en)	2012-02-28	2015-01-07	Grünenthal GmbH	Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
CA2862297A1 (en)	2012-02-29	2013-09-06	SinuSys Corporation	Devices and methods for dilating a paranasal sinus opening and for treating sinusitis
AU2013248351B2 (en)	2012-04-18	2018-04-26	Grunenthal Gmbh	Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9814671B2 (en)	2013-03-15	2017-11-14	Taris Biomedical Llc	Drug delivery devices and methods for drug delivery
MX2015012367A (es)	2013-03-15	2016-05-31	Taris Biomedical Llc	Dispositivos de suministro de farmacos con un componente permeable al farmaco y metodos.
AR096438A1 (es)	2013-05-29	2015-12-30	Gruenenthal Gmbh	Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
AU2014273227B2 (en)	2013-05-29	2019-08-15	Grunenthal Gmbh	Tamper-resistant dosage form containing one or more particles
US9687263B2 (en)	2013-05-30	2017-06-27	SinuSys Corporation	Devices and methods for inserting a sinus dilator
KR20160031526A (ko)	2013-07-12	2016-03-22	그뤼넨탈 게엠베하	에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
KR102385603B1 (ko) *	2013-08-19	2022-04-11	타리스 바이오메디컬 엘엘씨	다중 유닛 약물 전달 장치 및 방법
BR112016010482B1 (pt)	2013-11-26	2022-11-16	Grünenthal GmbH	Preparação de uma composição farmacêutica em pó por meio de criomoagem
AU2015261060A1 (en)	2014-05-12	2016-11-03	Grunenthal Gmbh	Tamper resistant immediate release capsule formulation comprising Tapentadol
MX2016015417A (es)	2014-05-26	2017-02-22	Gruenenthal Gmbh	Multiparticulas protegidas contra vertido de dosis etanolico.
EP3160544B1 (en) *	2014-06-25	2020-10-28	Min Wei	Medication infusion device
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3285850A1 (en)	2015-04-23	2018-02-28	TARIS Biomedical LLC	Drug delivery devices with drug-permeable component and methods
WO2016170097A1 (en)	2015-04-24	2016-10-27	Grünenthal GmbH	Tamper-resistant dosage form with immediate release and resistance against solvent extraction
MX2017015504A (es)	2015-06-03	2018-05-15	Intarcia Therapeutics Inc	Sistemas de colocacion y remoción de implante.
JP2018526414A (ja)	2015-09-10	2018-09-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
CA3024479A1 (en)	2016-05-16	2017-11-23	Intarcia Therapeutics, Inc.	Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
CN110225762A (zh)	2017-01-03	2019-09-10	因塔西亚制药公司	包括glp-1受体激动剂的连续施用和药物的共同施用的方法
DK3432970T3 (da)	2017-02-01	2021-05-10	Taris Biomedical Llc	In vivo lægemiddelleveringsindretninger
USD933219S1 (en)	2018-07-13	2021-10-12	Intarcia Therapeutics, Inc.	Implant removal tool and assembly
CN109589491B (zh) *	2019-01-29	2024-01-09	上海安翰医疗技术有限公司	自动给药装置
WO2024075723A1 (ja) *	2022-10-07	2024-04-11	テルモ株式会社	薬剤投与装置
WO2024202782A1 (ja) *	2023-03-30	2024-10-03	テルモ株式会社	投与装置、及び被投与物の投与状態の判断方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3625214A (en) *	1970-05-18	1971-12-07	Alza Corp	Drug-delivery device
US4874388A (en)	1987-06-25	1989-10-17	Alza Corporation	Multi-layer delivery system
US4976966A (en) *	1988-12-29	1990-12-11	Alza Corporation	Delayed release osmotically driven fluid dispenser
US5234693A (en)	1990-07-11	1993-08-10	Alza Corporation	Delivery device with a protective sleeve
GB9027422D0 (en)	1990-12-18	1991-02-06	Scras	Osmotically driven infusion device
US5288214A (en)	1991-09-30	1994-02-22	Toshio Fukuda	Micropump
US5639477A (en)	1993-06-23	1997-06-17	Alza Corporation	Ruminal drug delivery device
JP3251294B2 (ja)	1994-11-10	2002-01-28	ユニヴァーシティオブケンタッキーリサーチファウンデーション	体内に薬剤を直接送出する、移植・補充可能な放出制御装置
US6132420A (en)	1996-02-02	2000-10-17	Alza Corporation	Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6261584B1 (en)	1996-02-02	2001-07-17	Alza Corporation	Sustained delivery of an active agent using an implantable system
EP0877599B1 (en)	1996-02-02	2003-03-26	Alza Corporation	Sustained delivery of leuprolide using an implantable system
US5976109A (en)	1996-04-30	1999-11-02	Medtronic, Inc.	Apparatus for drug infusion implanted within a living body
ZA981610B (en)	1997-03-24	1999-08-26	Alza Corp	Self adjustable exit port.
MY125849A (en)	1997-07-25	2006-08-30	Alza Corp	Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
EP1041975B1 (en)	1997-12-22	2002-09-04	Alza Corporation	Rate controlling membranes for controlled drug delivery devices
JP4173635B2 (ja)	1997-12-29	2008-10-29	インターシアセラピューティクス，インコーポレイティド	膜プラグ保持機構を有する浸透供給装置
PT1736145E (pt) *	1997-12-30	2012-03-16	Intarcia Therapeutics Inc	Sistema de entrega de agente benéfico com obturador de membrana
US6245357B1 (en) *	1998-03-06	2001-06-12	Alza Corporation	Extended release dosage form
US6436091B1 (en)	1999-11-16	2002-08-20	Microsolutions, Inc.	Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US6283949B1 (en)	1999-12-27	2001-09-04	Advanced Cardiovascular Systems, Inc.	Refillable implantable drug delivery pump
US6464688B1 (en)	2000-02-15	2002-10-15	Microsolutions, Inc.	Osmotic pump delivery system with flexible drug compartment
US6471688B1 (en)	2000-02-15	2002-10-29	Microsolutions, Inc.	Osmotic pump drug delivery systems and methods

2004
- 2004-09-29 BR BRPI0414941-6A patent/BRPI0414941A/pt not_active IP Right Cessation
- 2004-09-29 US US10/953,895 patent/US7241457B2/en not_active Expired - Lifetime
- 2004-09-29 KR KR1020067006074A patent/KR20060097008A/ko not_active Application Discontinuation
- 2004-09-29 CA CA002538043A patent/CA2538043A1/en not_active Abandoned
- 2004-09-29 MX MXPA06002967A patent/MXPA06002967A/es not_active Application Discontinuation
- 2004-09-29 CN CNA2004800284968A patent/CN1859900A/zh active Pending
- 2004-09-29 WO PCT/US2004/031983 patent/WO2005032524A2/en active Application Filing
- 2004-09-29 JP JP2006534056A patent/JP2007507513A/ja not_active Withdrawn
- 2004-09-29 AU AU2004277980A patent/AU2004277980A1/en not_active Abandoned
- 2004-09-29 EP EP04785259A patent/EP1682099A2/en not_active Withdrawn
2006
- 2006-03-13 IL IL174294A patent/IL174294A0/en unknown
- 2006-04-28 ZA ZA200603420A patent/ZA200603420B/en unknown

Also Published As

Publication number	Publication date
WO2005032524A2 (en)	2005-04-14
CN1859900A (zh)	2006-11-08
CA2538043A1 (en)	2005-04-14
WO2005032524A3 (en)	2005-05-26
KR20060097008A (ko)	2006-09-13
BRPI0414941A (pt)	2006-11-07
EP1682099A2 (en)	2006-07-26
MXPA06002967A (es)	2006-06-14
US7241457B2 (en)	2007-07-10
JP2007507513A (ja)	2007-03-29
IL174294A0 (en)	2006-08-01
US20050107772A1 (en)	2005-05-19
AU2004277980A1 (en)	2005-04-14

Publication	Publication Date	Title
US7241457B2 (en)	2007-07-10	Osmotically driven active agent delivery device providing an ascending release profile
EP1613389B8 (en)	2008-05-07	Osmotic pump with means for dissipating internal pressure
EP0877599B1 (en)	2003-03-26	Sustained delivery of leuprolide using an implantable system
US20010031277A1 (en)	2001-10-18	Sustained delivery of an active agent using an implantable system
US20050010196A1 (en)	2005-01-13	Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
EP1246662B1 (en)	2005-08-31	Osmotic beneficial agent delivery system
CA2244997C (en)	2007-05-01	Sustained delivery of an active agent using an implantable system
AU724061C (en)	2007-04-19	Sustained delivery of an active agent using an implantable system